secwatch.observer — SEC 8-K summary
======================================

Issuer:     VYNE Therapeutics Inc. (VYNE)
CIK:        0001566044
Form:       8-K
Filed at:   2024-12-12T23:59:59+00:00
Accession:  0001104659-24-127997
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02, 5.07, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Stockholders approve 1.52M share increase in 2023 Equity Incentive Plan at annual meeting
--------------------------------------------------------------------------------

- Increase of 1,520,000 shares to 2023 Plan; total reserve now 1,651,907 shares.
- Eliminated 'liberal' share recycling for stock options and SARs.
- Incentive stock option limit raised to 3,619,586 shares.
- David Domzalski and Patrick LePore re-elected as Class III directors.
- Baker Tilly ratified as auditor; say-on-pay approved; advisory vote set for every year.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1566044/000110465924127997/0001104659-24-127997-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1566044/000110465924127997/tm2430841d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-127997

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer